Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04280601
Other study ID # 19-0039-E
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2020
Est. completion date March 1, 2023

Study information

Verified date March 2023
Source Mount Sinai Hospital, Canada
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective study will assess if 12 months of vitamin D3 (cholecalciferol) supplementation, in patients with AAV (GPA, MPA, and EGPA) who have deficient or insufficient 25(OH)D3 status at enrollment, correlates with improved disease activity and/or lower frequency of relapse (compared to historical data and a previously conducted cross sectional study (part I) that assessed vitamin D status in a cohort of similar patients).


Description:

1. Subject cohorts: Patients with a diagnosis of AAV from the MSH Rheumatology clinic in a cohort of consecutive patients over a 3 month recruitment period. 2. Study Design, Data Collection: Patients with insufficient and/or deficient vitamin D status at study enrolment will be instructed to take 12 months of vitamin D3 (cholecalciferol) supplementation (1000 IU for those not on vitamin D, or to increase the dose up to 2000 IU per day for those already on vitamin D) vs. those with sufficient status who will be observed for 12-months. 3. Study Duration: 12 months. 4. Study Endpoints: Vitamin D status vs. disease activity.


Recruitment information / eligibility

Status Completed
Enrollment 102
Est. completion date March 1, 2023
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Patients at least 18 years of age, women and men - Followed at the Mount Sinai Hospital, Vasculitis clinic, Toronto - With a diagnosis of AAV (GPA, MPA or EGPA) satisfying the modified American College of Rheumatology 1990 classification criteria and/or the revised 2012 Chapel Hill nomenclature definition. Exclusion criteria: - Current or history of hypercalcemia, primary hyperparathyroidism, sarcoidosis, hypervitaminosis D, Williams syndrome, other autoimmune, chronic inflammatory or infectious conditions, malabsorptive disorders, cancer, type 1 diabetes, liver disease - Current or planned pregnancy within the next year. - Intolerance, allergy to oral vitamin D, and/or contra-indication to take oral vitamin D

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
vitamin D
Patients with insufficient and/or deficient vitamin D status (<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months

Locations

Country Name City State
Canada Mount Sinai Hospital, Vasculitis clinic Toronto

Sponsors (1)

Lead Sponsor Collaborator
Christian Pagnoux

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease activity and disease relapse (using BVAS) Number of patients with active disease (BVAS score) or disease relapse (new item on the BVAS, in patients previously in remission) between enrollment and month 12, according to the study arm intervention (normal baseline vitamin D level vs. low baseline level and asked to increase vitamin D intake) 12 months
Secondary Renal function (GFR) Number of patients with progressive renal AAV-related disease (worsening GFR) in each study arm between enrollments and month 12 12 Months
Secondary Cardiovascular events Number of patients with cardiovascular events (IM, stroke) in each study arm between enrollments and month 12 12 Months
Secondary Interstitial lung disease diagnosis or progression (imaging and PFT) Number of patients with new diagnosis of ILD or worsening of ILD in each study arm (based on clinical, and either imaging and/or PFT findings) between enrollments and month 12 12 Months
Secondary Glucocorticoid use (and cumulative dose, mg) Use of glucocorticoids (including cumulative dose) in each study arm between enrollment and month 12 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01729624 - PRO Development for ANCA Associated Vasculitis N/A
Terminated NCT02474888 - Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis
Active, not recruiting NCT02198248 - Low-dose Glucocorticoid Vasculitis Induction Study Phase 4
Completed NCT02190916 - Vasculitis Illness Perception (VIP) Study N/A
Recruiting NCT01241305 - One-Time DNA Study for Vasculitis
Completed NCT00748644 - Efficacy Study of Two Treatments in the Remission of Vasculitis Phase 3
Recruiting NCT02967068 - VCRC Tissue Repository
Completed NCT01731561 - Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Phase 3
Not yet recruiting NCT06350110 - Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Not yet recruiting NCT02126098 - Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis N/A
Completed NCT02190942 - VCRC Patient Contact Registry Patient-Reported Data Validation Study
Terminated NCT01586858 - Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study N/A
Completed NCT00307593 - RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides N/A
Completed NCT02190929 - Educational Needs of Patients With Systemic Vasculitis N/A
Terminated NCT01408836 - Plasma Exchange for Renal Vasculitis Phase 2/Phase 3
Terminated NCT05376319 - PR3-AAV Resilient Remission or PRRR Phase 2
Completed NCT02476292 - Impact of Vasculitis on Employment and Income N/A
Completed NCT02169219 - Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Phase 4
Completed NCT01613599 - An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Active, not recruiting NCT05716334 - Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator